uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy

Aug. 08, 2022 10:01 AM ETuniQure N.V. (QURE)By: Dania Nadeem, SA News Editor

Quarterly results


  • uniQure (NASDAQ:QURE) is trading 27% down premarket after the company reported lower-than-expected Q2 revenue.
  • The company also announced that it was postponing the trial of a higher dose of AMT-130 to treat Huntington’s disease procedures due to recent suspected unexpected severe adverse reactions.
  • In July, the company reported to the health authorities suspected unexpected severe adverse reactions in three of the 14 patients treated with the higher dose of AMT-130.
  • However, the company said lower-dose procedures were not affected and it continues to expect on anticipated data readouts in 2023.
  • Revenue fell ~100% to $0.5M, and missed estimates by $8.71M, while a loss of -$0.84 beat by $0.11.
  • Cost of contract revenues for the quarter was nil compared to $23.2M, a year earlier.
  • Research and development expenses were $46.2M compared to $32.8M, due to preclinical development of temporal lobe epilepsy (AMT-260) advancing the clinical development of the company’s Huntington’s disease gene therapy program, and recruitment of personnel to support the development of product candidates.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.